<\/p>\n\n\n\n
Legal basis:<\/strong> Article 17(1) of the MAR Regulation \u2013 Inside Information, 7:11 p.m.<\/p>\n\n\n\n The Management Board of Celon Pharma S.A. (the \u201cCompany\u201d) hereby announces that on May 5, 2026, it was informed that four of the Company\u2019s applications for project funding (the \u201cProjects\u201d), submitted under the Medical Research Agency\u2019s (Agencja Bada\u0144 Medycznych, \u201cABM\u201d) Competition for the Development of Research and Development Projects in the Field of Translational Medicine \u2013 TRANSMED I (ABM\/2024\/8), have been recommended for funding. The total amount of funding awarded to the Projects is PLN 39.28 million.<\/p>\n\n\n\n The following Projects have been recommended for funding:<\/p>\n\n\n\n 1. Development of a First-in-Class Next-Generation Bispecific ADC Targeting Both Tumor and Immune Components in the Treatment of Solid Tumors (HERLICON)<\/strong><\/p>\n\n\n\n Awarded funding:<\/strong> PLN 11.98 million<\/p>\n\n\n\n The HERLICON project concerns the development of an innovative, first-in-class bispecific antibody-drug conjugate (bispecific ADC) therapeutic candidate designed to simultaneously target tumor and immune components in the treatment of solid tumors. The project is aligned with the Company\u2019s strategy of developing advanced targeted oncology therapies.<\/p>\n\n\n\n 2. Development of a Subcutaneous mRNA\/LNP Delivery Platform<\/strong><\/p>\n\n\n\n Awarded funding:<\/strong> PLN 11.86 million<\/p>\n\n\n\n The project involves the development of a technology platform enabling the subcutaneous administration of therapeutic mRNA\/LNP formulations, particularly through the use of lipid nanoparticles (LNPs) in combination with hyaluronidase. The objective is to create a technology that enables more efficient and patient-friendly delivery of mRNA therapies, with potential applications including the treatment of hemophilia A and other chronic diseases.<\/p>\n\n\n\n 3. Identification of the Mechanism of Action and Translational Validation of CPL\u2019280 \u2013 a Novel Non-Opioid Analgesic Candidate for the Treatment of Neuropathic Pain<\/strong><\/p>\n\n\n\n Awarded funding:<\/strong> PLN 11.08 million<\/p>\n\n\n\n The project includes the identification of the mechanism of action and translational validation of CPL\u2019280, an innovative non-opioid analgesic drug candidate being developed for the treatment of neuropathic pain. The objective is to enhance the scientific and development value of the program by confirming its mechanism of action and its potential for further clinical development.<\/p>\n\n\n\n